Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Presence of Differentiating Neuroblasts in Bone Marrow is a Favorable Prognostic Factor for Bone Marrow Metastatic Neuroblastoma at Diagnosis

  • Park, Sang Hyuk (Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center) ;
  • Kim, Sollip (Department of Laboratory Medicine, Ilsan Paik Hospital, Inje University College of Medicine) ;
  • Park, Chan-Jeoung (Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center) ;
  • Jang, Seongsoo (Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center) ;
  • Chi, Hyun-Sook (Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center) ;
  • Koh, Kyung-Nam (Department of Pediatrics, University of Ulsan College of Medicine and Asan Medical Center) ;
  • Im, Ho Joon (Department of Pediatrics, University of Ulsan College of Medicine and Asan Medical Center) ;
  • Seo, Jong Jin (Department of Pediatrics, University of Ulsan College of Medicine and Asan Medical Center)
  • Published : 2013.03.02
⟨ Previous Next ⟩

Abstract

Background: The prognostic impact of the presence of differentiating neuroblasts in bone marrow (BM) remains unclear in BM metastatic neuroblastoma (NB). We aimed to identify the prognostic impact of differentiating neuroblasts in BM at diagnosis and after chemotherapy. Methods: A total of 51 patients diagnosed with BM metastatic NB at Asan Medical Center between January 1990 and July 2005 were enrolled. BM histology and laboratory data along with overall survival (OS) were compared with regard to the differentiation status of neuroblasts in BM at diagnosis and after chemotherapy. Results: Among the 51 patients, 13 (25.5%) exhibited differentiating neuroblasts in BM at diagnosis and 17/51 (33.3%) exhibited them after chemotherapy. The only significant difference among patient groups was the improved OS in patients with differentiated neuroblasts in BM at diagnosis (P =0.021). In contrast, the differentiation status of neuroblasts in BM after chemotherapy did not affect OS (P =0.852). Conclusions: Our study is the first report describing the presence of differentiating neuroblasts in BM. The presence of differentiating neuroblasts in BM at diagnosis may be a favorable prognostic factor for patients with BM metastatic NB; however, the same phenomenon after chemotherapy is irrelevant to prognosis.

Keywords

References

  1. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 1999;86:349-63. https://doi.org/10.1002/(SICI)1097-0142(19990715)86:2<349::AID-CNCR20>3.0.CO;2-Y
  2. Peuchmaur M, d'Amore ES, Joshi VV, Hata J, Roald B, Dehner LP, et al. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 2003;98:2274-81. https://doi.org/10.1002/cncr.11773
  3. Howman-Giles R, Shaw PJ, Uren RF, Chung DK. Neuroblastoma and other neuroendocrine tumors. Semin Nucl Med 2007;37:286-302. https://doi.org/10.1053/j.semnuclmed.2007.02.009
  4. Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RP, D'Angio G, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1988;6:1874-81. https://doi.org/10.1200/JCO.1988.6.12.1874
  5. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106-20. https://doi.org/10.1016/S0140-6736(07)60983-0
  6. Haas D, Ablin AR, Miller C, Zoger S, Matthay KK. Complete pathologic maturation and regression of stage IVS neuroblastoma without treatment. Cancer 1988;62:818-25. https://doi.org/10.1002/1097-0142(19880815)62:4<818::AID-CNCR2820620430>3.0.CO;2-K
  7. Iwanaka T, Yamamoto K, Ogawa Y, Arai M, Ito M, Kishimoto H, et al. Maturation of mass-screened localized adrenal neuroblastoma. J Pediatr Surg 2001;36:1633-6. https://doi.org/10.1053/jpsu.2001.27935
  8. McLaughlin JE and Urich H. Maturing neuroblastoma and ganglioneuroblastoma: a study of four cases with long survival. J Pathol 1977;121:19-26. https://doi.org/10.1002/path.1711210104
  9. Rozmus J, Langer M, Murphy JJ, Dix D. Multiple persistent ganglioneuromas likely arising from the spontaneous maturation of metastatic neuroblastoma. J Pediatr Hematol Oncol 2012;34:151-3. https://doi.org/10.1097/MPH.0b013e318221ca82
  10. Eklof O, Sandstedt B, Thonell S, Ahstrom L. Spontaneous regression of stage IV neuroblastoma. Acta Paediatr Scand 1983;72:473-6. https://doi.org/10.1111/j.1651-2227.1983.tb09752.x
  11. Lonergan GJ, Schwab CM, Suarez ES, Carlson CL. Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: radiologic-pathologic correlation. Radiographics 2002;22:911-34. https://doi.org/10.1148/radiographics.22.4.g02jl15911
  12. Schmidt ML, Lukens JN, Seeger RC, Brodeur GM, Shimada H, Gerbing RB, et al. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study. J Clin Oncol 2000;18:1260-8. https://doi.org/10.1200/JCO.2000.18.6.1260
  13. Bagatell R, Rumcheva P, London WB, Cohn SL, Look AT, Brodeur GM, et al. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy. J Clin Oncol 2005;23:8819-27. https://doi.org/10.1200/JCO.2004.00.2931
  14. Tornoczky T, Semjen D, Shimada H, Ambros IM. Pathology of peripheral neuroblastic tumors: significance of prominent nucleoli in undifferentiated/ poorly differentiated neuroblastoma. Pathol Oncol Res 2007;13:269-75. https://doi.org/10.1007/BF02940304
  15. Ogita S, Tokiwa K, Arizono N, Takahashi T. Neuroblastoma: incomplete differentiation on the way to maturation or morphological alteration resembling maturity? Oncology 1988;45:148-52. https://doi.org/10.1159/000226552
  16. Ben Arush MW, Ben Itzhak O, Yossilevski G, El Hasid R, Postovsky S, Israel O. Neuroblastoma maturation by [$^{131}I$] metaiodobenzylguanidine in chemoresistant neuroblastoma. Med Pediatr Oncol 1999;33:418-9. https://doi.org/10.1002/(SICI)1096-911X(199910)33:4<418::AID-MPO18>3.0.CO;2-9
  17. Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ. Retinoid therapy of high-risk neuroblastoma. Cancer Lett 2003;197:185-92. https://doi.org/10.1016/S0304-3835(03)00108-3
  18. Calvo W and Forteza-Vila J. Schwann cells of the bone marrow. Blood 1970;36:180-8.
  19. Nakagawara A, Ikeda K, Tasaka H. Dopaminergic neuroblastoma as a poor prognostic subgroup. J Pediatr Surg 1988;23:346-9. https://doi.org/10.1016/S0022-3468(88)80204-5
  20. Candito M, Thyss A, Albertini M, Deville A, Politano S, Mariani R, et al. Methylated catecholamine metabolites for diagnosis of neuroblastoma. Med Pediatr Oncol 1992;20:215-20. https://doi.org/10.1002/mpo.2950200306

Cited by

  1. Morphologic Alteration of Metastatic Neuroblastic Tumor in Bone Marrow after Chemotherapy vol.47, pp.5, 2013, https://doi.org/10.4132/koreanjpathol.2013.47.5.433
  2. MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastoma vol.17, pp.None, 2017, https://doi.org/10.1186/s12935-017-0412-z